As many as 796 products—at various development stages—comprise the active pain pipeline currently, which makes it one of the most dynamic pipelines in the healthcare industry. This diverse array of molecular targets is composed of approximately 122 first-in-class development programs that are at the active stage – translated into percentage, this number comes to 13.6 (according to a study by GBI research). The fact that this pipeline is one of the most innovative ones in the industry is further proven by the fact that the active-stage development programs are acting on a remarkable 65 first-in-class molecular targets.
On the other hand, the pain therapeutics market fades in comparison to this innovation-centered arena of active pain management. The former only features sporadic innovation, and is largely defined by its unremarkable degree of product innovation over the last ten years. Change is hard to come by because of the lack of fresh blood in the pain therapeutics market, which continues to be dominated by long-standing active pharma ingredients.
Here are notable trends shaping the pain pipeline:
- Unmet needs create market for innovative pain management : As things stand today, the market for treating pain ranging from moderate-to-severe is predominantly occupied by opioids. This segment, however, is being subjected to widespread reformulation in a bid to ensure abuse resistance. On the other hand, mild pain is largely addressed using Non-Steroidal Anti-Inflammatory Drugs (NSAID). This leaves a significant demand for treating neuropathic pain subtypes unmet. These pain subtypes do not show any response to the existing set of therapies as these therapies are not in line with the core molecular pathophysiological profile.
- First-in-class innovation poised to expand current range of drug classes : Although it is mostly centered on drugs that are still in the early stages of development, the market for first-in-class innovation is largely composed of novel molecular targets associated with central sensitization for neuropathic pain. Considering that neuropathic pain is among the most difficult to manage and treat, first-in-class innovation could potentially alter the very characteristics of the future market by leading to new drug classes being formed.
- With M&A scenario active, investors will be rewarded : The current pain deals landscape is looking like a very diverse space. It has been so over the past seven to eight years. According to market research experts, about 261 licensing deals in the pain market have been reported since 2008. Moreover, the number of co-development deals has been pegged at 112. Interestingly, the investment activity is high without a doubt, but the numbers of deals for first-in-class products are few and far between. About half of all deals pertaining to first-in-class targets were closed right at the initial stages of development. This shows that companies are willing to take risks when it comes to first-in-class products despite having the option to ink deals at the later stage of drug development. This, strategic consolidations will be many to satisfy unmet needs.
Browse the full Press Release of Pain Therapies Market : http://www.mrrse.com/frontier-pharma-pain-market-report
Over the next few years, the pain market will be characterized by innovation and more patents being filed.